Abstract

The research of new therapeutic agents to fight bacterial infections has recently focused on the investigation of antimicrobial peptides (AMPs), the most common weapon that all organisms produce to prevent invasion by external pathogens. Among AMPs, the amphibian Temporins constitute a well-known family with high antibacterial properties against Gram-positive and Gram-negative bacteria. In particular, Temporin-L was shown to affect bacterial cell division by inhibiting FtsZ, a tubulin-like protein involved in the crucial step of Z-ring formation at the beginning of the division process. As FtsZ represents a leading target for new antibacterial compounds, in this paper we investigated in detail the interaction of Temporin L with Escherichia coli FtsZ and designed two TL analogues in an attempt to increase peptide-protein interactions and to better understand the structural determinants leading to FtsZ inhibition. The results demonstrated that the TL analogues improved their binding to FtsZ, originating stable protein-peptide complexes. Functional studies showed that both peptides were endowed with a high capability of inhibiting both the enzymatic and polymerization activities of the protein. Moreover, the TL analogues were able to inhibit bacterial growth at low micromolar concentrations. These observations may open up the way to the development of novel peptide or peptidomimetic drugs tailored to bind FtsZ, hampering a crucial process of bacterial life that might be proposed for future pharmaceutical applications.

Highlights

  • IntroductionNew resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases

  • The emergence of resistant bacteria is rising to dangerously high levels worldwide

  • Temporin L belongs to a well-known family of small, linear antibiotic peptides with

Read more

Summary

Introduction

New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. Several well-known infections are becoming harder, and sometimes impossible, to treat, as the efficacy of antibiotics is hampered by antimicrobial resistance. The research and development of new therapeutic agents to fight bacterial infections should be prioritized. In this respect, growing interest has recently focused on the investigation of antimicrobial peptides (AMPs) as new possible human therapeutics, alone or in combination with current antibiotics. AMPs are currently considered promising candidates as alternative therapeutic agents because of their broad spectrum of activity against several different microorganisms, their ability to inhibit bacterial growth and decrease the development of bacterial resistance [4,5]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call